S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Immunocore (IMCR) Stock Price, News & Analysis

$55.68
+0.94 (+1.72%)
(As of 04/19/2024 ET)
Today's Range
$53.79
$56.15
50-Day Range
$53.37
$74.52
52-Week Range
$42.21
$76.98
Volume
447,723 shs
Average Volume
395,392 shs
Market Capitalization
$2.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.55

Immunocore MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
44.7% Upside
$80.55 Price Target
Short Interest
Bearish
9.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.73mentions of Immunocore in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.54) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Medical Sector

518th out of 907 stocks

Biological Products, Except Diagnostic Industry

81st out of 149 stocks

IMCR stock logo

About Immunocore Stock (NASDAQ:IMCR)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Stock Price History

IMCR Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
IMCR Apr 2024 45.000 put
IMCR Apr 2024 95.000 call
Immunocore presented two posters at CROI 2024
Key Takeaways From Immunocore Hldgs Analyst Ratings
Immunocore FY 2023 Earnings Preview
Immunocore Holdings Ltd (IMCR)
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
497
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$80.55
High Stock Price Target
$91.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+44.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-55,290,000.00
Pretax Margin
-24.41%

Debt

Sales & Book Value

Annual Sales
$249.43 million
Book Value
$7.42 per share

Miscellaneous

Free Float
46,981,000
Market Cap
$2.77 billion
Optionable
Optionable
Beta
0.89
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 63)
    CEO & Director
    Comp: $1.42M
  • Mr. Brian R. Di Donato M.B.A. (Age 57)
    CFO & Head of Strategy
  • Mr. John Trainer M.B.A. (Age 50)
    SVP & Chief Operating Officer
  • Mr. John Goll III
    SVP, Finance & Chief Accounting Officer
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Mr. Sean D. Buckley (Age 41)
    VP & Chief Information Officer
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Margaret Hepworth
    General Counsel & Company Secretary
  • Ms. Elizabeth Varki Jobes Esq. (Age 57)
    J.D., Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications

IMCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings
or view top-rated stocks.

What is Immunocore's stock price target for 2024?

12 brokerages have issued 12 month price objectives for Immunocore's shares. Their IMCR share price targets range from $63.00 to $91.00. On average, they anticipate the company's stock price to reach $80.55 in the next year. This suggests a possible upside of 44.7% from the stock's current price.
View analysts price targets for IMCR
or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2024?

Immunocore's stock was trading at $68.32 at the beginning of the year. Since then, IMCR stock has decreased by 18.5% and is now trading at $55.68.
View the best growth stocks for 2024 here
.

Are investors shorting Immunocore?

Immunocore saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,610,000 shares, an increase of 7.5% from the March 15th total of 4,290,000 shares. Based on an average daily trading volume, of 491,700 shares, the days-to-cover ratio is presently 9.4 days. Approximately 9.5% of the company's shares are sold short.
View Immunocore's Short Interest
.

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our IMCR earnings forecast
.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.12. The company had revenue of $70.16 million for the quarter, compared to the consensus estimate of $53.25 million. Immunocore had a negative trailing twelve-month return on equity of 15.78% and a negative net margin of 22.48%. Immunocore's revenue was up 22.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) earnings per share.

When did Immunocore IPO?

Immunocore (IMCR) raised $199 million in an IPO on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

Who are Immunocore's major shareholders?

Immunocore's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.18%) and Hennion & Walsh Asset Management Inc. (0.04%).
View institutional ownership trends
.

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMCR) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners